IP in the digital age: a tricky path ahead for pharma companies?

13-09-2016

Stephen Bennett, Elisabethann Wright, Mark Marfe and James Cross

IP in the digital age: a tricky path ahead for pharma companies?

Syda Productions / Shutterstock.com

The pharmaceutical industry needs to adjust its expectations of the scope of IP protection available in the digital age, say Stephen Bennett, Elisabethann Wright and Mark Marfe of Hogan Lovells, and James Cross of RGC Jenkins.

The pharmaceutical industry is becoming increasingly interested in digital health and serious money is being invested in the technology. 

For example, Roche has invested in mySugr, a company that offers an app to help patients manage their diabetes, and Propeller Health is a company working on connected inhaler technology with GSK, Aptar and Boehringer Ingelheim. 

Pharmaceutical companies are used to an established commercial formula for bringing new products to market, with product development involving a significant up-front investment including research and development costs and generating the requisite quality, safety and efficacy data.


Hogan Lovells, RGC Jenkins, Stephen Bennett, Elisabethann Wright, Mark Marfe, trademark, digital age, European Commission, patent, MA,

LSIPR